Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06153095




Registration number
NCT06153095
Ethics application status
Date submitted
22/11/2023
Date registered
1/12/2023
Date last updated
31/05/2024

Titles & IDs
Public title
A Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE)
Scientific title
A Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of IMPT-514 in Participants With Active, Refractory Lupus Nephritis and Systemic Lupus Erythematosus
Secondary ID [1] 0 0
MPCT-021N
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Systemic Lupus Erythematosus 0 0
Lupus Nephritis 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - IMPT-514
Other interventions - IMPT-514
Other interventions - IMPT-514

Experimental: Phase 1 Lupus Nephritis - Administration of IMPT-514

Experimental: Phase 2 Lupus Nephritis - Administration of IMPT-514

Experimental: Phase 2 SLE without Lupus Nephritis - Administration of IMPT-514


Other interventions: IMPT-514
CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide

Other interventions: IMPT-514
CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide

Other interventions: IMPT-514
CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Phase I: Incidence of dose limiting toxicities (DLTs), serious adverse events (SAEs), and other treatment-emergent adverse events (TEAEs).
Timepoint [1] 0 0
Baseline to Month 6
Primary outcome [2] 0 0
Phase I: Incidence of TEAEs, percent reduction in peripheral B cells, and the proportion of enrolled participants who receive the target dose.
Timepoint [2] 0 0
Baseline to Month 6
Primary outcome [3] 0 0
Phase II: Cohort 1: Proportion of participants with Complete Renal Response (CRR) as defined by EULAR/ERA-EDTA at Month 6.
Timepoint [3] 0 0
Baseline to Month 6
Primary outcome [4] 0 0
Phase II: Cohort 2: Proportion of participants achieving DORIS remission at Month 6.
Timepoint [4] 0 0
Baseline to Month 6

Eligibility
Key inclusion criteria
1. Willing and able to provide written informed consent

2. Age 18 years of age or older

3. Weight > 45 kg at enrollment

4. Adequate blood pressure control

5. Diagnosis of SLE by 2019 European League Against Rheumatism (EULAR)/American College
of Rheumatology (ACR) classification criteria or 2012 Systemic Lupus Collaborating
Clinics (SLICC) criteria, including positive ANA or positive anti-dsDNA

6. LN participants: Active, biopsy-proven, proliferative lupus nephritis Class III or IV
by 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria

Other protocol-defined criteria apply.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

1. Any clinically significant underlying illness, other than SLE and LN, which would pose
a safety risk or concern, as determined by the Investigator

2. Any other systemic autoimmune condition

3. Rapidly progressive glomerulonephritis

4. Active central nervous system (CNS) lupus

5. History of allogeneic bone marrow or stem cell transplantation or solid organ
transplantation

Other protocol-defined criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/02/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/02/2027
Actual
Sample size
Target
30
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 0 0
NSW 2145 - Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Iowa
Country [3] 0 0
United States of America
State/province [3] 0 0
Michigan
Country [4] 0 0
United States of America
State/province [4] 0 0
Ohio

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
ImmPACT Bio
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of
IMPT-514, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation
(CD)19 and CD20 in participants with active, refractory lupus nephritis and systemic lupus
erythematosus.

IMPT-514 treatment consists of a single infusion of CAR-transduced autologous T cells
administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine
and cyclophosphamide. Individual participants will remain in the active post-treatment period
for approximately 1 year.

Participants will continue in long-term follow-up for 15 years from treatment.
Trial website
https://clinicaltrials.gov/ct2/show/NCT06153095
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06153095